The Lupus Book: A Guide for Patients and Their Families, Third Edition (54 page)

Hahn),
xi

32, 162–64, 171, 172;
biopsies,
146–48;

duodenum,
134

blood testing,
65–68, 118, 162–64;
defining

dysphagia,
133–34

lupus,
5–9,
7
;
difficulties,
3–4;
drug studies,

262–63;
fibromyalgia,
176–79;
genitourinary

ears,
123, 208

evaluation,
60, 62;
head and neck review,

ecchymoses,
70, 75–76

60, 61;
historical background,
9–10;
HLA

echinacea,
188,
206, 258

testing,
39–40;
infections,
237–38;
late-onset

economic impact of lupus,
252–54

lupus,
168–69;
lupus band test,
76–77,
77,

education,
257

171, 172;
lymphatic symptoms,
157–58;

eicosapentaenoic acid,
45

medication complications,
116–17;

elbows,
81

misdiagnosis,
12, 159, 162–63, 171–72;

elderly patients,
168–69

mouth symptoms,
72, 123–24;
MS panel,

electrical studies,
119

107;
muscular symptoms,
82–83;
neonatal

electrocardiogram,
102

lupus,
166;
neurologic symptoms,
62, 105–

electroencephalograms (EEGs),
119–20

8, 109–16, 118–20;
organ-system approach,

electromyograms (EMGs),
120

57;
osteoporosis,
240–41;
physical exam,
61–

ELISA test,
67

62;
and pregnancy,
248;
primary symptoms,

embolisms,
91–92

62–64;
prognosis,
255–60;
pulmonary

emotional issues,
195, 197, 198–99

symptoms,
85–94;
review of systems,
59–61;

endocardium,
99

rheumatology,
4, 59,
62,
257;
Rose Bengal

endocrine system,
61, 128–29, 223

staining,
125;
second opinions,
196;

endomyocardial biopsy,
98

Sjo¨gren’s syndrome,
124–25;
sun sensitivity,

endothelial cells,
162

183;
ultrasonic diagnosis,
86, 157–58

environmental causes of lupus,
36,
37

dialysis,
232, 255, 260

environmental conditions,
43–48

diarrhea,
136

environmental pollution,
47

diclofenac,
210, 212

eosin,
45

diet,
184–86, 224,
241

eosinophilic fasciitis,
45

diffuse interstitial lung disease,
90–91

eosinophilic myalgic syndrome (EMS),
45

disability from lupus,
252–54

eosinophils,
18,
19, 21,
155

discoid lupus erythematosus (DLE): and

ephedra,
258

alopecia,
72;
diagnosing,
5–7, 70–71, 170;

epidemiology of lupus,
11, 256

lesions,
121;
lupus band test,
77;
and

erythrocytes,
17

nicotine,
194;
and pregnancy,
244;

erythropoietin (EPO),
153, 176, 234–35

prognosis,
256;
and skin pigmentation,
73.

esophageal manometry,
134–35

See also
cutaneous lupus

esophageal reflux,
94–95

diuretics,
50, 140

esophagus,
133,
134

divorce rates,
202

estrogens,
50, 127–29, 230–31, 241,
241,
250

DongQuai,
188

ethical issues,
32–33

D-penincillamine,
54

etodolac,
211

Dressler’s syndrome,
54

evening primrose,
188

drug abuse,
173

exercise,
186–91, 257–58

drug-induced lupus erythematosus (DILE):

extremity evaluation,
62

clinical features,
53–54;
diagnosing,
5, 7,

exudates,
88, 138

170;
differentiating from SLE,
54;

eyes,
106, 122–23, 124, 218

epidemiology,
51–55;
and pregnancy,
244;

prognosis,
256;
and renal function,
148;

families of patients,
41–42, 202–3

suspect drugs,
49–50,
51
;
treating,
54–55;

family planning,
249–50

and tumor necrosis factor,
264

Farr test,
67

drugs.
See
medications;
specific drug names

fatigue,
64, 192–93, 252

and types

fear associated with lupus,
197

dry mouth,
124

feet,
82

[284]

Index

fengucreek,
188

G6PD deficiency,
232

fennel,
188

granulocytes,
17,
19, 21, 23

fenoprofen,
210

Grave’s disease,
42, 130

fertility,
132, 225, 243, 249–50

growth factors,
234

fetal health,
248–49

guided imagery,
199

fever,
63

Guillain-Barre syndrome,
111

fibromyalgia: anger associated with,
198;

guilt associated with lupus,
198–99

distinguishing from lupus,
171;
GI

problems,
136;
incidence in lupus patients,

hair-coloring solutions,
44

118
;
and livedo reticularis,
75;
in lupus hair loss,
72

patients,
81–82;
and nervous system,
111–12;

hands,
81

relationship to lupus,
176–79;
tender points,

haplotypes,
40, 41

177

Hargraves, Malcolm,
10

fish oils,
45, 185

Hashimoto’s thyroiditis,
42, 130

fluorinated steroids,
220

H blockers,
137, 224

2

flurbiprofen,
210

headaches,
105, 107, 109–10,
118

folic acid,
186, 227

head and neck review,
60, 61

Food and Drug Administration (FDA),
261–62

hearing problems,
123, 208

foods associated with lupus,
45–46

heart,
94–102,
101,
166

forme fruste lupus,
170

heartburn,
133, 135–36, 223

Fox, Robert,
216

Hebra, Ferdinand von,
9

functional bowel disease,
136

Helicobacter pylori,
137

functional syndromes,
116

hematocrit,
152

fungal infections,
237

hematology,
60–61, 152

Furst, Dan,
186

hematuria,
146

Furst, Elaine,
186

hemodialysis,
232

future of lupus research,
261–66

hemoglobin,
152

hemorrhages,
92, 138–39, 225, 234

gallbladder,
134

Hench, Phillip,
10, 219

gamma globulins,
20,
21,
156, 233, 238, 246

heparin,
246

gangrene,
75

hepatic vasculitis,
141

garlic,
188

hepatomegaly,
141

gastroesophageal reflux disease (GERD),
95

herbs,
186,
187–90,
206

gastrointestinal system,
60, 95, 133–43,
134,

hiatal hernia,
135

223–24

Hippocrates,
9

G-CSF,
234–35

hips,
82

gender and lupus: hormonal causes,
127;

histones,
29

prevalence in women,
3, 12,
13,
256;

history of lupus,
9–10, 59–61, 104–5

research bias,
4.
See also
sex and lupus

HIV/AIDS,
175–76

genetics,
39–42;
and animal research,
33;

hives,
73–74

lupus genes,
35, 248;
and lupus outcomes,

HLA-DR4 genetic marker,
52

256;
prevalence of lupus,
13;
research on,

Hoffman, Byron,
49

261;
and SLE development,
37

homocysteine,
68

genitourinary evaluation,
60, 62

honey,
189

gentian,
189

hormones,
127–32;
adverse reactions,
230;
and

geographic distribution of lupus,
13, 47

birth control,
50;
diseases associated with,

gingko biloba,
186,
189

130–32, 241;
hormonal pathways,
128
;

ginseng,
189

hormone preparations,
221
;
imbalances,
173;

glands,
157.
See also
lymphatic system

lupus’ impact on,
128;
and menstrual

glaucoma,
122, 218

problems,
129–30;
noncontraceptive,
230–31;

globulin,
21

research on,
264;
role in lupus development,

glomerulonephritis,
144–48

35;
understanding,
127.
See also specific

glomerulus,
144,
145

hormones

goldenseal,
189

Hughes, Graham,
104, 160

Index

[285]

human leukocyte antigen (HLA) system,
23–

information sources on lupus,
xi

24,
24,
35, 39,
40,
41

insurance,
254

hydralazine,
53

interferons,
20–21,
22,
114

hydrazines,
44, 193–94

interleukins,
20–21,
22,
25, 114

hydrocortisone,
221,
221–22

interstitial lung disease (ILD),
90

hydroxychloroquine (Plaquenil),
125–26, 215–

interstitial nephritis,
149

18, 245, 262

intestine,
134

hypercoagulable state,
162

iritis,
122

hypertension,
92–93, 102, 117, 244, 260

iron,
193

hyperthyroidism,
54

iron-deficiency anemia,
153

hyperviscosity syndrome,
68, 109,
118,
234

irradiation,
234

hypoplasia,
154

irritable bowel syndrome,
136

hypothalamus,
127,
128,
219–20

isoniazid,
53

ibuprofen,
50, 209, 210

jaundice,
141

idiopathic thrombocytopenic purpura (ITP),

Jenner, Edward,
239

156, 175

joints,
78–82,
79,
191

idiotypes,
27

I.G. Farbenindustrie,
214

Kaiser-Permanente,
13, 256

immune system: abnormalities,
37
;
components

Kaposi, Moriz,
9, 104

of,
17–22;
decreasing immune response,
37;

Keil, Harry,
159

immune ablative therapy,
265–66;
immune

keratinocytes,
69

deposits,
76–77;
immunophylles,
264;

keratoconjunctivitis sicca,
124

immunoregulatory chemicals,
128;

Keterolac,
211

immunosuppressive therapies,
150, 225–28,

ketoprofen,
210, 212

228,
264–66;
and the rheumatic review,
60–

kidneys.
See
renal problems

61;
and stress,
200.
See also specific

Kikuchi’s syndrome,
157

components

Klemperer, Paul,
9

immunoglobulins,
21
;
abnormal responses,
36–

Klinefelter’s syndrome,
129

37;
and antiphospholipid syndrome,
160;

knees,
79,
82

and antiplatelet antibodies,
31;
and B cells,

25;
formation of,
19
;
and immune response, laboratory variables,
5,
7,
256

20;
and neonatal lupus,
165

Lancet,
215

incidence of lupus,
3–4, 11–13, 173.
See also

large intestine,
134

diagnosis and assessment

larynx,
124

indomethacin,
148, 209, 210–11

lasers,
234